These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 1471873)

  • 1. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.
    Fahn S; Cohen G
    Ann Neurol; 1992 Dec; 32(6):804-12. PubMed ID: 1471873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidation reactions in Parkinson's disease.
    Olanow CW
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 32-7; discussion 37-9. PubMed ID: 2215972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Free oxygen radiacals and kidney diseases--part I].
    Sakac V; Sakac M
    Med Pregl; 2000; 53(9-10):463-74. PubMed ID: 11320727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative mechanisms in nigral cell death in Parkinson's disease.
    Jenner P
    Mov Disord; 1998; 13 Suppl 1():24-34. PubMed ID: 9613715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease?
    Andersen JK
    Novartis Found Symp; 2001; 235():11-20; discussion 20-5. PubMed ID: 11280021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB; Ben-Shachar D; Riederer P
    Mov Disord; 1993; 8(1):1-12. PubMed ID: 8419792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What process causes nigral cell death in Parkinson's disease?
    Jenner P
    Neurol Clin; 1992 May; 10(2):387-403. PubMed ID: 1584181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB; Ben-Shachar D; Riederer P
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modifications of the iron-neuromelanin system in Parkinson's disease.
    Fasano M; Bergamasco B; Lopiano L
    J Neurochem; 2006 Feb; 96(4):909-16. PubMed ID: 16417570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotoxicity and neuroprotection in Parkinson's disease.
    Lange KW; Youdim MB; Riederer P
    J Neural Transm Suppl; 1992; 38():27-44. PubMed ID: 1491247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.
    Dexter DT; Sian J; Rose S; Hindmarsh JG; Mann VM; Cooper JM; Wells FR; Daniel SE; Lees AJ; Schapira AH
    Ann Neurol; 1994 Jan; 35(1):38-44. PubMed ID: 8285590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron metabolism and Parkinson's disease.
    Hirsch EC; Faucheux BA
    Mov Disord; 1998; 13 Suppl 1():39-45. PubMed ID: 9613717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
    Hirsch E; Graybiel AM; Agid YA
    Nature; 1988 Jul; 334(6180):345-8. PubMed ID: 2899295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
    Cohen G
    J Neural Transm Suppl; 1983; 19():89-103. PubMed ID: 6321651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress in Parkinson's disease and other neurodegenerative disorders.
    Jenner P
    Pathol Biol (Paris); 1996 Jan; 44(1):57-64. PubMed ID: 8734302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oxidative stress and the brain].
    Tanaka M
    Nihon Ronen Igakkai Zasshi; 1997 Sep; 34(9):706-10. PubMed ID: 9430979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
    J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.